Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transdermal nitroglycerin in angina pectoris.

J O Parker, H L Fung

    The American Journal of Cardiology
    |September 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Transdermal nitroglycerin (TGTN) patches provided short-term angina relief but failed to offer 24-hour protection. Tolerance developed with sustained use, limiting long-term antianginal efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Domestic dog health worsens with socio-economic deprivation of their home communities.

    Acta tropica·2014
    Same author

    Environmental variabilities and the distribution of octocorals and black corals in Hong Kong.

    Marine pollution bulletin·2014
    Same author

    Comparison of methods for analyzing kinetic data from mechanism-based enzyme inactivation: application to nitric oxide synthase.

    AAPS pharmSci·2001
    Same author

    Relationship between pharmacokinetics and hemodynamic effects of inhaled isobutyl nitrite in conscious rats.

    AAPS pharmSci·2001
    Same author

    Systemic biochemical effects of inhaled NO in rats: increased expressions of NOS III, nitrotyrosine-, and phosphotyrosine-immunoreactive proteins in liver and kidney tissues.

    Nitric oxide : biology and chemistry·2001
    Same author

    Nitroglycerin-induced relaxation of anorectal smooth muscle: evidence for apparent lack of tolerance development in the anaesthetized rat.

    British journal of pharmacology·2001
    Same journal

    Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

    The American journal of cardiology·2026
    Same journal

    ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

    The American journal of cardiology·2026
    Same journal

    Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

    The American journal of cardiology·2026
    Same journal

    Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

    The American journal of cardiology·2026
    Same journal

    Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

    The American journal of cardiology·2026
    Same journal

    Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

    The American journal of cardiology·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Chronic stable angina pectoris significantly impacts patient quality of life.
    • Nitroglycerin is a cornerstone therapy for angina, but its delivery methods are continuously evaluated.

    Purpose of the Study:

    • To evaluate the hemodynamic and antianginal efficacy of transdermal nitroglycerin (TGTN) patches.
    • To determine the optimal dosage and duration of TGTN for sustained angina relief.
    • To assess the development of tolerance to TGTN during chronic administration.

    Main Methods:

    • Acute dosing studies with varying TGTN patch sizes (5-15 mg GTN) in patients with stable angina.
    • Treadmill exercise testing was used to assess antianginal effects at 2, 4, and 24 hours post-application.
    • A 1-2 week daily therapy study with 30-cm2 TGTN patches was conducted, comparing exercise tolerance to placebo.

    Related Experiment Videos

    Main Results:

    • Acute TGTN application improved treadmill walking time at 2 and 4 hours, but not consistently at 24 hours.
    • Larger TGTN patch sizes (up to 90 cm2) showed limited 24-hour efficacy.
    • Sustained daily TGTN therapy (30-cm2 patches) for 1-2 weeks resulted in exercise tolerance similar to placebo.

    Conclusions:

    • Current TGTN patch sizes are insufficient for achieving 24-hour antianginal protection.
    • Tolerance to the antianginal effects of TGTN develops during sustained daily therapy.
    • Alternative or adjunctive strategies may be necessary for long-term angina management with nitroglycerin.